Literature DB >> 26259507

Reconstituted AIM2 inflammasome in cell-free system.

Naoe Kaneko1, Yuki Ito1, Tomoyuki Iwasaki1, Hiroyuki Takeda2, Tatsuya Sawasaki2, Kiyoshi Migita3, Kazunaga Agematsu4, Atsushi Kawakami5, Shinnosuke Morikawa1, Sho Mokuda1, Mie Kurata1, Junya Masumoto6.   

Abstract

Absent in melanoma 2 (AIM2) is an intracellular pattern-recognition receptor, which is a member of the PYHIN protein family, consisting of a PYD domain and an IFN-inducible nuclear localization (HIN) domain. AIM2 is reported to oligomerize with adaptor protein ASC upon sensing bacterial and viral cytosolic DNA in order to form the AIM2 inflammasome, which activates caspase-1 leading to IL-1β secretion. Dysregulation of AIM2 inflammasome is supposed to result in autoinflammatory and autoimmune diseases. Thus, the development of new targeted drugs against AIM2 inflammasome would be important for the treatment of these diseases. However, since AIM2 inflammasome is an intracellular receptor, enforced internalization of both ligands and candidate molecules is necessary for the screening of AIM2-inflammasome-targeted molecules. We developed a reconstituted AIM2 inflammasome in a cell-free system with amplified luminescent proximity homogeneous assay (Alpha). Strong Alpha signal was detected upon incubation with poly-deoxyadenylic-deoxythymidylic acid, poly(dA:dT), whereas no Alpha signal was detected upon incubation with muramyl dipeptide, one of the NLR ligands of Nod2 ligand. The interaction between AIM2 and ASC was disrupted by an anti-human ASC monoclonal antibody, CRID3, a class of diarylsulfonylurea-containing compounds, and glycyrrhizin, a substance found in liquorice root. Thus, the reconstituted AIM2 inflammasome in a cell-free system is useful for screening AIM2-inflammasome-targeted therapeutic molecules.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIM2; ASC; Cell-free; Inflammasome; Reconstitution

Mesh:

Substances:

Year:  2015        PMID: 26259507     DOI: 10.1016/j.jim.2015.08.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Nod2-Nodosome in a Cell-Free System: Implications in Pathogenesis and Drug Discovery for Blau Syndrome and Early-Onset Sarcoidosis.

Authors:  Tomoyuki Iwasaki; Naoe Kaneko; Yuki Ito; Hiroyuki Takeda; Tatsuya Sawasaki; Toshio Heike; Kiyoshi Migita; Kazunaga Agematsu; Atsushi Kawakami; Shinnosuke Morikawa; Sho Mokuda; Mie Kurata; Junya Masumoto
Journal:  ScientificWorldJournal       Date:  2016-06-15

Review 2.  Applications of reconstituted inflammasomes in a cell-free system to drug discovery and elucidation of the pathogenesis of autoinflammatory diseases.

Authors:  Naoe Kaneko; Tomoyuki Iwasaki; Yuki Ito; Hiroyuki Takeda; Tatsuya Sawasaki; Shinnosuke Morikawa; Naoko Nakano; Mie Kurata; Junya Masumoto
Journal:  Inflamm Regen       Date:  2017-05-03

3.  AIM2 as a putative target in acute kidney graft rejection.

Authors:  Nathália Franchon Marques Tejada; João Vitor Ziroldo Lopes; Luis Eduardo Duarte Gonçalves; Izabela Mamede Costa Andrade da Conceição; Glória Regina Franco; Bruno Ghirotto; Niels Olsen Saraiva Câmara
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

4.  KN3014, a piperidine-containing small compound, inhibits auto-secretion of IL-1β from PBMCs in a patient with Muckle-Wells syndrome.

Authors:  Naoe Kaneko; Mie Kurata; Toshihiro Yamamoto; Tomonari Shigemura; Kazunaga Agematsu; Takashi Yamazaki; Hiroyuki Takeda; Tatsuya Sawasaki; Tomohiro Koga; Atsushi Kawakami; Akihiro Yachie; Kiyoshi Migita; Koh-Ichiro Yoshiura; Takeshi Urano; Junya Masumoto
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379

5.  A comprehensive interaction study provides a potential domain interaction network of human death domain superfamily proteins.

Authors:  Wei Zhou; Naoe Kaneko; Tomoya Nakagita; Hiroyuki Takeda; Junya Masumoto
Journal:  Cell Death Differ       Date:  2021-05-15       Impact factor: 15.828

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.